BMS’ Andreotti Talks BD Beyond 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology, virology and cardiovascular remain top therapeutic priorities in mid-term, but longer term focus at BMS is shifting to oncology, CNS and cardiovascular and metabolic diseases, CEO Lamberto Andreotti tells analysts at Sanford F. Bernstein conference.
Register for our free email digests: